ALS Association yearly report cards show no U.S. state earned the highest score for policies supporting patients; several had ...
The first patient has been dosed in a Phase 1/2 clinical study of VTx-002, an experimental therapy for amyotrophic lateral sclerosis.
Speakers on a Coya Therapeutics (NASDAQ:COYA) webinar outlined the company’s scientific rationale and clinical development ...
A Blue Bell startup is studying whether stabilizing mitochondria can slow progression in neurodegenerative disease.
Allowing people with disabilities to talk by just thinking about a word, that's what UC Davis researchers hope to accomplish with new cutting-edge technology. It can be a breakthrough for people with ...
A new drug may slow progression of — and even reverse — symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo in ALS ...
COUNTY SHERIFF’S DEPARTMENT. WELL, IMAGINE HAVING A MEDICINE HELPING TO KEEP YOU ALIVE AND SUDDENLY IT IS GONE. WE’RE HEARING FROM A WOMAN LIVING WITH ALS OR LOU GEHRIG’S DISEASE, WHO SAYS SHE MAY BE ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Researchers have found that patients with amyotrophic lateral sclerosis have ...
A simple non-invasive hair-based test could one day help with early diagnosis of amyotrophic lateral sclerosis (ALS)—improving patient care and potentially extending survival. This is the hope of ...
The Trump administration's proposed cuts to the National Institutes of Health would be devastating to the efforts to find a cure for the deadly disease. On May 7, I lost my dad to ALS, two years after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results